US HB4825 | 2017-2018 | 115th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on January 18 2018 - 25% progression, died in committee
Action: 2018-01-24 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Pending: House Subcommittee on Crime, Terrorism, Homeland Security, And Investigations Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 18 2018 - 25% progression, died in committee
Action: 2018-01-24 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Pending: House Subcommittee on Crime, Terrorism, Homeland Security, And Investigations Committee
Text: Latest bill text (Introduced) [PDF]
Summary
MEDS Act Marijuana Effective Drug Studies Act of 2018 This bill amends the Controlled Substances Act to establish a new, separate registration process to facilitate research involving marijuana and the commercial production of drugs made from marijuana. Specifically, the bill requires the Drug Enforcement Administration to register manufacturers and distributors to supply marijuana: (1) for use in research, and (2) for the commercial production of approved drugs containing or derived from marijuana.
Title
MEDS Act Marijuana Effective Drug Studies Act of 2018
Sponsors
Rep. Rob Bishop [R-UT] | Sen. John Curtis [R-UT] | Rep. Chris Stewart [R-UT] | Rep. Mia Love [R-UT] |
Rep. Jamie Raskin [D-MD] | Rep. Eleanor Norton [D-DC] | Rep. Jared Polis [D-CO] | Rep. Earl Blumenauer [D-OR] |
Sen. Jacky Rosen [D-NV] | Rep. Dana Rohrabacher [R-CA] | Rep. Jimmy Panetta [D-CA] | Rep. Steve Cohen [D-TN] |
Rep. James McGovern [D-MA] | Rep. Matt Gaetz [R-FL] | Rep. Drew Ferguson [R-GA] | Rep. Ro Khanna [D-CA] |
History
Date | Chamber | Action |
---|---|---|
2018-01-24 | House | Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. |
2018-01-19 | House | Referred to the Subcommittee on Health. |
2018-01-18 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2018-01-18 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2018-01-18 | House | Introduced in House |
Same As/Similar To
SB1803 (Related) 2017-09-13 - Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484)
Subjects
Administrative law and regulatory procedures
Alternative treatments
Crime and law enforcement
Drug safety, medical device, and laboratory regulation
Drug therapy
Drug trafficking and controlled substances
Health personnel
Licensing and registrations
Medical research
Research administration and funding
Alternative treatments
Crime and law enforcement
Drug safety, medical device, and laboratory regulation
Drug therapy
Drug trafficking and controlled substances
Health personnel
Licensing and registrations
Medical research
Research administration and funding
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/house-bill/4825/all-info |
Text | https://www.congress.gov/115/bills/hr4825/BILLS-115hr4825ih.pdf |